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Abstract
Background: Estrogens, environmental chemicals with carcinogenic potential, as well as oxidative
and carbonyl stresses play a very important role in breast cancer (BC) genesis and progression.
Therefore, polymorphisms of genes encoding enzymes involved in estrogen biosynthesis pathway
and in the metabolic activation of pro-carcinogens to genotoxic intermediates, such as cytochrome
P450C17α (CYP17), endogenous free-radical scavenging systems, such as glutathione S-transferase
(GSTP1) and paraoxonase 1 (PON1), and anti-glycation defenses, such as glyoxalase I (GLO1),
could influence individual susceptibility to BC. In the present case-control study, we investigated
the possible association of CYP17 A1A2, GSTP1 ILE105VAL, PON1 Q192R or L55M, and GLO1
A111E polymorphisms with the risk of BC.
Methods: The above-said five polymorphisms were characterized in 547 patients with BC and in
544 healthy controls by PCR/RFLP methods, using DNA from whole blood. To estimate the
relative risks, Odds ratios and 95% confidence intervals were calculated using unconditional logistic
regression after adjusting for the known risk factors for BC.
Results: CYP17 polymorphism had no major effect in BC proneness in the overall population.
However, it modified the risk of BC for certain subgroups of patients. In particular, among
premenopausal women with the A1A1 genotype, a protective effect of later age at menarche and
parity was observed. As to GSTP1 and PON1 192 polymorphisms, the mutant Val and R alleles,
respectively, were associated with a decreased risk of developing BC, while polymorphisms in
PON1 55 and GLO1 were associated with an increased risk of this neoplasia. However, these
findings, while nominally significant, did not withstand correction for multiple testing.
Conclusion: Genetic polymorphisms in biotransformation enzymes CYP17, GSTP1, PON1 and
GLO1 could be associated with the risk for BC. Although significances did not withstand correction
for multiple testing, the results of our exploratory analysis warrant further studies on the above
mentioned genes and BC.
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Background
Breast cancer (BC) is both the prevailing malignancy and
the most common cause of cancer death among women
in Western countries [1]. Estrogens, dietary factors, life-
style, environmental chemicals with carcinogenic poten-
tial, as well as oxidative and carbonyl stresses, play a very
important role in BC pathogenesis and progression [2-8].
It is, therefore, plausible that polymorphisms of genes
encoding enzymes involved in estrogen biosynthesis
pathway or metabolic activation of pro-carcinogens to
genotoxic intermediates, endogenous free-radical scav-
enging systems and anti-glycation defenses, may influ-
ence individual susceptibility to BC.
Much interest has long been addressed to cytochrome
P450c17α (CYP17) and glutathione S-transferase 1
(GSTP1) genes, encoding enzymes involved in estrogen
biosynthesis and metabolism [9] or in environmental car-
cinogens detoxification and exo- and endogenous xenobi-
otic transformation [10], respectively. Despite some
studies have confirmed a link between CYP17 [11-14] or
GSTP1 [15-18] gene polymorphisms and the risk of BC,
others have failed to find such an association [19-27] and
conflicting results have been obtained. Hence, the clinical
relevance of these polymorphic genes remains to be fully
elucidated and needs further investigation.
Moreover, the search for additional metabolizing poly-
morphic genes as potential susceptibility factors in BC, is
needed. In particular, paraoxonase 1 gene (PON1),
encodes a serum high-density lipoproteins (HDL)-associ-
ated enzyme [28], playing an important role in lipid
metabolism as an antioxidant molecule, through (a)
hydrolyzation of active oxidized phospholipids, (b)
destruction of lipid hydroperoxides and H2O2 (peroxi-
dase-like activity), (c) preservation of HDL integrity and
function and, finally, (d) prevention of LDL oxidation.
Additionally, paraoxonase 1 is consistently implicated in
the elimination of carcinogenic lipid-soluble radicals
from lipid peroxidation [29]. Therefore, it is reasonable to
expect that the activity of such an enzyme may influence
BC development. In particular, loss of the paraoxonase 1
care-take function could play an important role in increas-
ing the breast vulnerability to genomic damage caused by
inflammatory oxidants, dietary carcinogens, as well as in
estrogen-lipidic metabolism, that may modulate the pro-
gression of breast tumor. The main paraoxonase-encoding
gene, PON1, is polymorphic in human populations and
the expression of such a gene widely varies in human pop-
ulations [30]. Two common single-base mutation poly-
morphisms (SNP) have been described in the encoding
region of human PON1, which lead to glutamine →
arginine substitution at 192 (Q192R) or a leucine →
methionine substitution at 55 (L55M). Both these poly-
morphisms influence PON1 activity [31,32]. So far, very
few information is available about the association of
PON1/192 and 55 polymorphisms with BC risk and only
in selected populations [33,34]. It was, therefore, aim of
the present study also to analyze the relationships of
PON1 allelic variants with the risk of BC and to clarify the
question whether both gene variations might be useful
genetic markers of breast tumor.
Glyoxalase I (GLO1) gene encodes an anti-glycation
defence enzyme that decreases the concentration of dicar-
bonyl compounds (alpha-oxoaldehydes), such as methyl-
glyoxal (MG), the most reactive glycation precursor [35].
Since substantial evidence exists on the role of carbonyl
stress and DNA/protein glycation in relation to BC patho-
genesis [7,8], it is possible that allele variants in GLO1
gene may predispose to the risk of developing BC and
affect the course of the disease. A single nucleotide poly-
morphism in GLO1 gene, C419A, causing an Ala111Glu
(A111E) change in the protein sequence, has been
recently identified [36]. Therefore, since there are no exist-
ing data in this connection, we finally evaluated the distri-
bution of GLO1 A111E polymorphism among BC
patients as well as controls, to point out a possible associ-
ation with the risk of BC.
We would also like to highlight that all these four genes
have been simultaneously considered in the present study
because all related to the control of oxidative stress. In
fact, they encode for enzymes that detoxify free radicals or
reduce potential substrates for their production. As well
known, there is evidence that oxidative stress, resulting
from either an excess of reactive oxygen species (ROS) or
a deficiency in antioxidant capabilities, may play a role in
the etiology of BC [4,37]. In particular, CYP17 is respon-
sible for catecholestrogens (CEs) formation via estrogen
biosynthesis [38]. CEs can be oxidized to the correspond-
ing ortho-quinone derivatives with concomitant forma-
tion of ROS [39]. From this aspect, estrogens have been
proposed to trigger BC development via an initiating
mechanism involving CEs [38]. GSTP1 and PON1 encode
enzymes that carry out well known cellular mechanisms
of antioxidant defence, playing a key role in the removal
or detoxification of ROS, which is essential for preventing
oxidative damage [40]. Finally, GLO1 encodes an enzyme
that removes methylglyoxal (MG), a potent oxidative
stress precursor. Free radical generation given by MG
involves ROS, reactive nitrogen species (RNS), as well as
organic radicals like MG radial or cross-linked protein rad-
icals [41].
Methods
Patients
The study protocol followed the guidelines of our local
ethics committee and the investigation was conducted
with the ethical requirements defined in the Helsinki Dec-
laration. All patients gave their informed consent to par-
ticipate in the study.BMC Cancer 2009, 9:115 http://www.biomedcentral.com/1471-2407/9/115
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Caucasian Italian women with a clinical and histological
diagnosis of breast cancer (BC) (ductal carcinoma, 78.6%;
lobular carcinoma, 15.9%; papilla tubular carcinoma,
1.3%; other, 4.2%) were enrolled in this study between
June 2003 and July 2007 from the Breast Unit, Surgical
Department of the University of Perugia, Umbria, Italy.
Women with BC were identified via the Regional Cancer
Registry, to which reporting of all malignant tumors is
mandatory, and contacted via their doctors. In total, 547
women agreed to participate in the study, representing
89% of those who were contacted and found to be eligi-
ble. Histological staging of breast carcinoma was per-
formed according to the current classification of the
International Union Against Cancer [42]. Women show-
ing axillary lymph node-positive disease (n = 190) or met-
astatic BC (stage IV; n = 19) at diagnosis were considered
"advanced" cases. Women diagnosed with a tumor con-
fined to the breast, either in situ (n = 46) or invasive (n =
292), were designated as "local". The age at diagnosis of
BC was 55.3 ± 10.5 (SD) years and the patients had no
previous history of BC or any other cancer. Control
women (n = 544) were healthy Caucasian Italian women
as well, randomly selected from the Umbrian Registry of
Total Population, matched by age (55.0 ± 10.2 years; P =
0.11). The participation rate among controls was 87%. All
these subjects were asked to complete a self-administered
questionnaire on demographic factors, anthropometric
measures, menstrual, reproductive, and breast feeding his-
tories, use of contraceptives and exogenous hormones,
medical and screening histories, first-degree family his-
tory of BC, occupational exposure, smoking history and
alcohol consumption. All subjects were asked to provide
a blood sample, to be used for genotyping. The median
time between diagnosis and interview for BC cases was 2
months.
Primers and Polymerase Chain Reaction (PCR)
Genomic DNA was extracted from heparinized peripheral
whole blood, using the QIAamp Blood Mini Kit (Qiagen,
Milan, Italy). The nucleotide sequence of primers is
shown in Table 1. PCR amplification was carried out in a
final volume of 50 μl, containing 20 ng of DNA, 20
pmoles of each primer, 100 mM of each dNTP, 1.5 mM
MgCl2, 10 mM Tris-HCl pH 8.3, 50 mM KCl, and 1 U of
Taq DNA polymerase. DNA amplification was performed
conventionally; samples were subjected to 35 cycles of
amplification consisting of 40 sec. denaturation, 30 sec.
annealing, and 30 sec. extension. The final extension step
at 72°C was extended to 10 min. The annealing tempera-
ture was optimized for each primer set.
Genotyping
SNPs detection was based upon Restriction fragment
length polymorphism (RFLP) analysis after PCR amplifi-
cation. CYP17 gene maps to chromosome 10. A single T
(A1 allele) to C (A2 allele) nucleotide substitution in the
5'-untranslated region of CYP17 creates a recognition site
for the MspA1 restriction enzyme. GSTP1 gene has been
mapped to a small region of chromosome 11. The region
of genomic DNA flanking exon 5 of GSTP1 gene was
amplified. The A to G substitution in GSTP1 leads to the
creation of a recognition site for the Alw261 restriction
enzyme. PON1 gene is located at chromosome 7. Single-
base substitutions, which lead to a change of a glutamine
residue into arginine at amino acid position 192, and a
change of leucine to methionine affecting amino acid 55
of the paraoxonase protein encoded by human PON1,
create recognition sites for Alw1 (PON1/192) and NlaIII
(PON1/55), respectively. GLO1 gene maps to chromo-
some 6. A C to A substitution in GLO1 exon 4, which
changes Ala111Glu in the encoded protein, leads to the
loss of a recognition site for the SfaNI restriction enzyme.
PCR products were, therefore, digested for 3 hr at 37°C
using either MspA1, Alw261, Alw1, NlaIII, or SfaNI,
respectively, and separated by electrophoresis in 12%
polyacrylamide gels. The band patterns were developed by
silver staining to identify the single base pair change. All
genotyping was carried out by laboratory personnel
blinded to case-control status of the samples, which
included quality control samples for validation. Concord-
ance for quality control samples was 100%.
Table 1: Oligonucleotide primer sequences used for genotyping
Gene Oligonucleotides Sequence
(5'- 3')
Expected amplicon size (bp)
CYP17 230F CATTCGCACTTCTGGAGTC 459
642R GGCTCTTGGGGTACTTG
GSTP1 P105F ACCCCAGGGCTCTATGGGAA 176
P105R TGAGGGCACAAGAAGCCCCT
PON1 192 PON192F TATTGTTGCTGTGGGACCTGAG 99
PON192R CACGCTAAACCCAAATACATCTC
PON1 55 PON55F GAAGAGTGATGTATAGCCCCAG 170
PON55R TTTAATCCAGAGCTAATGAAAGCC
GLO1 GLO1F TCAGAGTGTGTGATTTCGTG 700
GLO1R CATGGTGAGATGGTAAGTGTBMC Cancer 2009, 9:115 http://www.biomedcentral.com/1471-2407/9/115
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Statistical Analysis
The obtained results were analyzed with the MedCalc sta-
tistical package (MedCalc, Mariakerke, Belgium). The
associations between CYP17, GSTP1, PON1, GLO1 alleles
and breast cancer (BC) were evaluated using uncondi-
tional logistic regression. All Odds ratio (ORs) and 95%
confidence intervals (CIs) were adjusted for potential
modifying factors, including age at menarche (continu-
ous, log transformed), age at first full-term pregnancy
(FFTP) (continuous, log transformed), history of benign
breast disease (yes, no), first-degree family history of
breast cancer (yes, no), waist-hip ratio (WHR) (continu-
ous, log transformed), use of oral contraceptive (yes, no),
alcohol consumption (ever, never), smoking habits (ever,
never), level of education (low, medium/high) and post-
menopausal use of estrogens (ever, never). Covariates as
body mass index (BMI), breast cysts and physical activity
were not included in the logistic model, because they did
not alter the OR by > 5%, either separately or in combina-
tion. Since risk factors for BC significantly vary depending
on menopausal status, we performed our analysis not
only in the overall population, but also in premenopausal
and postmenopausal subsets of women. Women who
reported natural menopause or had undergone bilateral
oophorectomy were classified as postmenopausal. Hyster-
ectomized women with intact ovaries/ovary and women
for whom the details of the operation were unknown were
also classified postmenopausal, if they were no longer
menstruating and were older than 50 years (median for
menopause in Italian women). All of the others were clas-
sified premenopausal. WHR, BMI, and age at FFTP were
dichotomized on the basis of the median values for pop-
ulation controls. Estimates of statistical significance were
calculated by standard χ2 analysis, or by Fisher's exact test,
where cell numbers were < 5. We used Bonferroni correc-
tion to account for multiple comparisons, and a two-
tailed P value < 0.000862 was considered statistically sig-
nificant.
Descriptive analysis included determination of standard
deviation (SD) for cases and controls as well as Student's
t-test to evaluate differences between means. A two sided
probability value of less than 0.05 was considered to indi-
cate statistical significance. For each group (controls and
cases), allele frequencies were calculated by direct gene
counting. Deviations from Hardy-Weinberg equilibrium
(HWE) were tested by χ2 test.
Results
Patients characteristics
The main characteristics of the study subjects (cases, n =
547; controls, n = 544) and potential risk factors for breast
cancer (BC) are shown in Table 2. The occurrence of pre-
menopausal women was higher among population con-
trols (42.3%) compared with BC patients (34.2%). The
mean age at menarche [14.0 ± 1.54 (SD) years for con-
trols, 14.2 ± 1.65 (SD) years for cases] and age at first term
pregnancy [24.9 ± 4.15 (SD) years for controls, 25.2 ±
4.65 (SD) years for cases] were quite similar in both
groups. First-degree family history of BC was associated
with an increased risk of this malignancy (OR, 2.63; 95%
CI, 1.60–4.40, P < 0.01). Quite weaker, but yet significant
associations were observed for the history of benign breast
disease (OR, 1.32; 95% CI, 1.02–1.72, P < 0.05) and
WHRs over 0.91 (OR, 1.49; 95% CI, 1.17–1.91, P < 0.01).
On the other hand, a significantly decreased risk was
observed for women who had ever used oral contracep-
tives (OR, 0.55; 95% CI, 0.40–0.71, P < 0.01), for women
with at least one child (OR, 0.60; 95% CI, 0.37–0.95, P <
0.01), and women aged 26–30 at FFTP (OR, 0.44; 95% CI,
0.30–0.65, P < 0.01). When tested for HWE, statistically
significant deviations were detected between the observed
and expected genotypic frequencies in all the tested genes,
except CYP17.
CYP17 polymorphism and BC risk
The distribution of CYP17 genotypes and the ORs associ-
ated with BC are shown in Table 3. The A2 allele did not
significantly affect BC risk, either in the overall popula-
tion or when women were grouped according to meno-
pausal status. No statistically significant differences were
observed either when case patients were considered by
tumor stage (Table 4). Conversely, we observed a protec-
tive effect of later age at menarche (≥ 13 years) among pre-
menopausal women with the A1A1 genotype (OR, 0.28;
95% CI, 0.10–0.71, P for interaction = 0.11) and for pre-
menopausal women with at least one child and the A1A1
genotype (OR, 0.26; 95% CI, 0.10–0.60, P for interaction
= 0.12) (Table 5). In contrast, an increased risk of BC with
borderline significance was observed for postmenopausal
women with A1A2 or A2A2 genotype and BMI > 25,4 Kg/
m2 (Table 5).
GSTP1 polymorphism and BC risk
The distribution of GSTP1 genotypes and the ORs associ-
ated with BC are shown in Table 6. We found that the fre-
quency of the Val allele was significantly lower in the BC
population than in the control group; 42% of the cases
and 76% of controls carried at least one Val allele. Patients
with the Ile/Val genotype and Val/Val genotype had a sig-
nificant decrease for BC risk compared with the Ile/Ile
genotype. Results were similar in pre- (46% of cases and
75% of controls were carriers of at least one Val allele) and
postmenopausal (40% of cases and 78% of controls were
carriers of at least one Val allele) women. No significant
association was found between GSTP1 polymorphism
and BC risk, according to tumor stage or potential hor-
mone-related BC risk factors (age at menarche, postmen-
opausal use of estrogens, use of oral contraceptives, parity,
age at FFTP, BMI or WHR) (data not shown).BMC Cancer 2009, 9:115 http://www.biomedcentral.com/1471-2407/9/115
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Table 2: Selected characteristics of the study subjects and potential risk factors for breast cancer
Cases (n = 547) (%) Controls (n = 544) (%) ORb (95% CI)
Menopausal status
Premenopausal 187 (34.2) 230 (42.3) 1.0
Postmenopausal 360 (65.8) 314 (57.7) 0.75 (0.44–1.29)
Age at menarche
<13 99 (18.1) 87 (16.0) 1.0
13–14 230 (42.0) 212 (39.0) 0.73 (0.54–1.06)
≥ 15 218 (39.9) 245 (45.0) 0.91 (0.62–1.26)
Age at FFTP
Nulliparous 116 (21.2) 65 (11.9) 1.0
≤ 25 269 (49.2) 296 (54.4) 0.76 (0.52–1.09)
26–30 107 (19.6) 138 (25.4) 0.44 (0.30–0.65)**
≥ 31 55 (10.0) 45 (8.3) 0.67 (0.38–1.12)
Number of full-term pregnancies
Nulliparous 116 (21.2) 65 (12.0) 1.0
1 77 (14.1) 72 (13.2) 0.60 (0.37–0.95)**
2 160 (29.2) 204 (37.5) 0.45 (0.32–0.63)*
3+ 194 (35.5) 203 (37.3) 0.55 (0.38–0.77)*
Use of oral contraceptives
Never 359 (65.6) 275 (50.6) 1.0
Ever 188 (34.4) 269 (49.4) 0.55 (0.40–0.71)**
Postmenopausal use of estrogen
Never 254 (70.6) 208 (66.2) 1.0
Ever 106 (29.4) 106 (33.8) 0.80 (0.60–1.02)
WHR
≤ 0.91 216 (39.5) 270 (49.6) 1.0
> 0.91 331 (60.5) 274 (50.4) 1.49 (1.17–1.91)**
BMI (kg/m2)
≤ 25.4 243 (44.4) 271 (49.8) 1.0
> 25.4 304 (55.6) 273 (50.2) 1.21 (0.96–1.55)
First-degree family history of breast cancer
No 485 (88.7) 519 (95.4) 1.0
Yes 62 (11.3) 25 (4.6) 2.63 (1.60–4.40)**
History of benign breast disease
No 340 (62.2) 375 (68.9) 1.0
Yes 207 (37.8) 169 (31.1) 1.32 (1.02–1.72)*
Educationa
Low 332 (60.7) 313 (57.5) 1.0
Medium 144 (26.3) 153 (28.1) 0.87 (0.66–1.15)
High 71 (13.0) 78 (14.4) 0.83 (0.57–1.25)
Current alcohol intake
Never 309 (56.5) 272 (50.0) 1.0
Once a month or less 153 (28.0) 172 (31.6) 0.76 (0.57–1.03)
Daily-weekly 85 (15.5) 100 (18.4) 0.74 (0.51–1.04)
Smoking habits
Nonsmokersc 415 (75.9) 396 (72.8) 1.0
Ex-smokersd 59 (10.8) 76 (14.0) 0.72 (0.49–1.07)
Current smokerse 73 (13.3) 72 (13.2) 0.95 (0.66–1.38)
aLow: none or primary school; medium: middle school; high: high school, trade school or university. bAdjusted for age. OR: odds ratio; CI: confidencial intervals; 
FFTP: first full-term pregnancy; WHR: waist-hip ratio; BMI: body mass index. cNonsmokers = Never smokers; dEx-smokers = tobacco consumption stopped from 
7.6 ± 4.2 years with a previous average tobacco consumption estimated at 47 pack-years (range, 20–106); e Current smokers = with an average tobacco 
consumption estimated at 43 pack-years (range, 20–200). *P < 0.05; **P < 0.01. The characteristics of participants with and without BC were compared by χ2 test 
for categorical variables.BMC Cancer 2009, 9:115 http://www.biomedcentral.com/1471-2407/9/115
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PON1 polymorphisms and BC risk
The associations between the Q192R or L55M polymor-
phisms and BC risk are shown in Table 7. As to PON1
Q192R, 11.5% of cases and 37.5% of controls were carri-
ers of at least one R allele. QR heterozygotes and mutant
RR homozygotes had a lower risk of the breast disease
compared to the QQ homozygotes. In particular, there
was a trend in decreasing the risk with the number of R
alleles. Results stratified by menopausal status at diagno-
sis, confirmed the OR of the general analysis only in the
case of postmenopausal group, where the association was
even more pronounced. In contrast, no significant associ-
ation was observed in the premenopausal group.
Concerning PON1 L55M, this polymorphism was associ-
ated with a significantly increased risk of BC. Eighty per-
cent of cases and 65% of controls were carriers of at least
one M allele. When stratified by menopausal status, the
frequency of the M allele was higher among both premen-
opausal (84%) and postmenopausal (79%) cases com-
pared with the respective frequencies (66% and 65%) in
the control subjects. Premenopausal women with the MM
genotype had a significant increase for BC risk compared
with the LL genotype. Postmenopausal women with the
LM and MM genotype had a significant increase for BC
risk compared with the LL genotype. PON1 Q192R and
L55M genotypes were then analyzed according to tumor
stage (Table 8). As to PON1 Q192R in the premenopausal
group, such a genotype was associated with a lower risk of
only advanced BC, compared with controls, while no sig-
nificant correlation was found for local BC. In particular,
premenopausal patients having advanced disease were
less frequently carriers of the R allele (16%) compared
with controls (37%). Heterozygotes QR and homozygotes
RR had a significant decrease for BC risk, compared with
the QQ genotype, resembling the ORs trend obtained for
the analysis in the overall population. In contrast, in pre-
menopausal women with local disease no such tendency
was observed. Thirty-six percent of cases and 37% of con-
trols carried at least one R allele. In the postmenopausal
group, association between PON1 Q192R genotypes and
BC risk was found for both local and advanced cases. We
found that significant decreases in the frequencies of the R
allele occurred for local as well as advanced BC. About 3%
of cases and 38% of controls carried at least one R allele in
both local and advanced postmenopausal group. By con-
trast, an increase was observed in the frequencies of the
PON1 55 M allele in both local and advanced premeno-
pausal BC groups, with respect to the control cohort, thus
suggesting an increased risk of BC. In particular, 85% of
cases and 66% of controls were carriers of at least one R
allele, in the local premenopausal group, and 82% of
cases and 66% of controls were carriers of at least one R
allele, in the advanced premenopausal group. A similar
trend was observed in postmenopausal women. In partic-
ular, individuals with the PON1 55 LM and MM geno-
types showed an increased risk of advanced BC. Potential
hormone-related BC risk factors (age at menarche, post-
menopausal use of estrogens, use of oral contraceptives,
parity, age at FFTP, BMI or WHR) did not modify the asso-
ciation of either Q192R or L55M SNPs with BC (data not
shown).
GLO1 polymorphism and BC risk
The distribution of GLO1 genotypes and the ORs associ-
ated with BC are shown in Table 9. We found that 78% of
cases and 42% of controls were carriers of at least one E
allele. When stratified by menopausal status, the fre-
quency of the E allele was higher among both premeno-
pausal (79%) and postmenopausal (78%) cases
compared with the respective frequencies (55% and 32%)
in the control subjects. Patients with the AE genotype and
Table 3: Associations between CYP17 genotype and breast cancer according to menopausal status
A1A1 A1A2 A2A2 A1A2 and A2A2
All
Cases, n (%) 229 (41.9) 258 (47.1) 60 (11.0) 318 (58.1)
Controls, n (%) 227 (41.7) 249 (45.8) 68 (12.5) 317 (58.3)
OR (95% CI)a 1.0 0.95 (0.72–1.24) 0.77 (0.51–1.20)b 0.90 (0.70–1.18)
Menopausal status at diagnosis
Premenopausal
Cases, n (%) 88 (47.1) 81 (43.3) 18 (9.6) 99 (52.9)
Controls, n (%) 100 (43.5) 99 (43.0) 31 (13.5) 130 (56.5)
OR (95% CI)a 1.0 0.88 (0.56–1.36) 0.66 (0.33–1.29)b 0.83 (0.55–1.25)
Postmenopausal
Cases, n (%) 141 (39.2) 177 (49.2) 42 (11.6) 219 (60.8)
Controls, n (%) 127 (40.4) 150 (47.8) 37(11.8) 187 (59.5)
OR (95% CI)a 1.0 0.98 (0.68–1.41) 0.94 (0.53–1.68)b 0.97 (0.69–1.38)
aAdjusted for age, age at menarche, age at FFTP, number of full term pregnancies, first-degree family history of breast cancer, history of benign 
breast disease, use of oral contraceptives, WHR, alcohol consumption, smoking habits, level of education and postmenopausal use of estrogen. bP 
for trend: all, 0.221; premenopausal, 0.389; postmenopausal, 0.954.BMC Cancer 2009, 9:115 http://www.biomedcentral.com/1471-2407/9/115
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EE genotype had a significant increased BC risk compared
with the AA genotype. Results stratified by menopausal
status at diagnosis (Table 9) and according to tumor stage
(Table 10) confirmed the ORs of the general analysis. No
significant association was found between GLO1 poly-
morphism and BC risk according to potential hormone-
related BC risk factors (age at menarche, postmenopausal
use of estrogens, use of oral contraceptives, parity, age at
FFTP, BMI or WHR) (data not shown).
Combination of CYP17, GSTP1, PON1-192, PON1-55 and 
GLO1 polymorphisms as predictive factor for BC risk
The analysis of a single polymorphism alone is often not
indicative for the association to the risk of BC. We believe
that the combination of them all in each single case may
be a more predictive factor for the risk of this neoplasia.
Therefore, since these genes are all related to the control
of oxidative stress-inducing mechanisms, we would like to
emphasize that the detection of the GSTP1IleVal-PON1/
192QR-PON1/55LM-GLO1AE or GSTP1IleIle-PON1/
192QQ-PON1/55MM-GLO1EE genotype combination at
individual level, might lead to the identification of
patients with intermediate and high risk for BC, respec-
tively (Table 11), compared to the GSTP1ValVal-PON1/
192RR-PON1/55LL-GLO1AA genotype combination.
None of the SNPs was significantly associated with the
risk of BC after controlling for multiple testing by Bonfer-
roni analysis (data not shown).
Discussion
The aetiological factors implicated in breast carcinogene-
sis are unclear, but estrogen levels [2], lifestyle factors,
especially diet [43], oxidative and carbonyl stresses [4-8]
have all been suggested to influence breast cancer (BC)
risk. The human body has a number of enzyme systems
protecting from genotoxic damage, acting either indi-
rectly, via reduction of potential substrates giving free rad-
icals production, such as cytochrome P450c17α (CYP17)
[38,39] or, directly, via free radical detoxification, such as
glutathione S-transferase (GSTP1), paraoxonase (PON1)
[40] and glyoxalase 1 (GLO1) [41]. Polymorphisms of
these genes are believed to be key factors in determining
cancer susceptibility to toxic or environmental chemicals
[29,44,45]. Therefore, in an effort to increase our under-
standing of the interaction between potential carcino-
genic environmental exposure and genetic factors in the
pathogenesis and predisposition to BC disease risk, we
determined the frequencies and the relative risks (ORs) of
CYP17, GSTP1, PON1 and GLO1 gene polymorphisms in
a control population and in a population of patients with
breast tumor. In agreement with the majority of studies
[19-21,23,24] on CYP17 polymorphism and BC risk, our
results did not reveal any significant association between
the CYP17 A2 allele and the risk of BC. Conversely, the
present study revealed that CYP17 polymorphism may
lower the risk of BC in premenopausal women with the
A1A1 genotype and later age at menarche or with at least
one child, in accordance with the results obtained by oth-
ers [19-21]. Our observations may be compatible with the
hypothesis that the protection against BC is reduced
among women with the A2 allele containing genotypes,
because of elevated baseline levels of circulating steroid
hormones. In addition, results from a previous study indi-
cate that nulliparous women with the A2A2 genotype
have higher mean levels of serum estradiol than those
with the A1A1 genotype [46]. Moreover, the fact that the
observed associations were mainly confined to premeno-
Table 4: Associations between CYP17 genotype and breast cancer according to menopausal status and tumor stage
A1A1 A1A2 A2A2 A1A2 and A2A2
Premenopausal
Controls, n (%) 100 (43.5) 99 (43.0) 31 (13.5) 130 (56.5)
Cases by stage
Local, n (%) 48 (43.6) 50 (45.5) 12 (10.9) 62 (56.4)
OR (95% CI)a 1.0 1.02 (0.61–1.71) 0.76 (0.35–1.66)b 0.96 (0.58–1.56)
Advanced, n (%) 41 (53.2) 30 (39.0) 6 (7.8) 36 (46.8)
OR (95% CI)a 1.0 0.63 (0.35–1.25) 0.43 (0.16–1.16)c 0.57 (0.32–1.01)
Postmenopausal
Controls, n (%) 127 (40.4) 150 (47.8) 37(11.8) 187 (59.6)
Cases by stage
Local, n (%) 93 (40.8) 105 (46.0) 30 (13.2) 135 (59.2)
OR (95% CI)a 1.0 1.01 (0.65–1.52) 1.07 (0.57–2.16)d 1.02 (0.68–1.53)
Advanced, n (%) 47 (35.6) 73 (55.3) 12 (9.1) 85 (64.4)
OR (95% CI)a 1.0 0.98 (0.59–1.64) 0.87 (0.37–2.05)e 0.97 (0.62–1.53)
aAdjusted for age, age at menarche, age at FFTP, number of full term pregnancies, first-degree family history of breast cancer, history of benign 
breast disease, use of oral contraceptives, WHR, alcohol consumption, smoking habits, level of education and postmenopausal use of estrogen. bP 
for trend = 0.591; cP for trend = 0.061; dP for trend = 0.835; eP for trend = 0.829.BMC Cancer 2009, 9:115 http://www.biomedcentral.com/1471-2407/9/115
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pausal women, could reflect differences in the nature of
premenopausal and postmenopausal BC etiology [47]
and suggest that CYP17 gene polymorphism may play a
different role in later onset of the disease.
As to GSTP1, we found that the major risk for BC was asso-
ciated with individuals homozygotes for the Ile allele,
while the Val allele appeared to be a protective factor
against BC. A similar trend was presumably related with
an activation of the enzyme at tissue level. Besides, exper-
imental evidences showed that the Val variant may have
either lower or higher specific activity and affinity depend-
ing on the substrate [48]. On this aspect, our findings may
differ from those of other studies showing an increased
risk for women carrying the Val allele, due to different
environmental exposure and/or dietary habits. Our results
are instead consistent with other studies where a tendency
of decreased risk could be seen for the GSTP1 Val allele
[25,26]. As well known, oxidative stress and free radicals
induced by environmental and/or endogenous carcino-
gens have been associated with increased risk of BC [4-6].
Regarding PON1, we found that women with PON1-192/
QR and RR genotype had a lower risk of BC in comparison
to women with the PON1-192/QQ genotype. This might
be explained since, as expected, the Q to R substitution
lead to the production of an enzyme with a higher detoxi-
fication activity against potentially carcinogenic products
of oxidative stress and lipid peroxidation. This is sup-
ported by a quite recent study showing that individuals
Table 5: Associations between CYP17 genotypes and breast cancer risk stratified by selected characteristics
Premenopausal Postmenopausal
A1A1 A1/A2 and A2A2 A1A1 A1/A2 and A2A2
Case/Control ORa (95% CI) Case/Control ORa (95% CI) Case/Control ORa (95% CI) Case/Control ORa (95% CI)
Age at 
menarche
< 13 yr 25/11 1.0 23/26 1.0 19/25 1.0 32/25 1.0
≥ 13 yr 64/89 0.28 
(0.10–0.71)
75/104 0.77 
(0.39–1.53)
119/103 1.31 
(0.63–2.72)
190/161 0.84 
(0.44–1.61)
Postmenopaus
al use of 
estrogen
Never 100/89 1.0 154/119 1.0
Ever 39/40 1.15 
(0.63–2.12)
67/66 0.86 
(0.52–1.41)
Use of oral 
contraceptives
Never 28/27 1.0 33/32 1.0 106/86 1.0 192/130 1.0
Ever 64/74 1.01 
(0.45–2.27)
62/97 0.55 
(0.29–1.03)
32/41 0.83 
(0.41–1.74)
30/57 0.52 
(0.29–0.98)
Parity
Nulliparous 21/9 1.0 14/15 1.0 30/16 1.0 51/25 1.0
Parous 68/91 0.26 
(0.10–0.60)
84/115 0.77 
(0.32–1.94)
109/109 0.53 
(0.25–1.08)
170/164 0.97 
(0.36–1.17)
Age at FFTP 
for parous 
women
≤ 25 yr 48/47 1.0 51/66 1.0 65/64 1.0 105/119 1.0
> 25 yr 22/35 0.83 
(0.45–1.55)
33/43 1.34 
(0.61–2.89)
43/42 0.92 
(0.53–1.65)
64/63 0.59 
(0.28–1.47)
BMI
≤ 25,4 63/67 1.0 51/76 1.0 53/51 1.0 76/77 1.0
> 25,4 28/35 0.60 
(0.27–1.34)
45/52 1.05 
(0.57–1.93)
86/76 1.43 
(0.75–2.72)
145/110 1.64 
(0.97–2.78)
WHR
< 0,91 41/58 1.0 42/72 1.0 47/58 1.0 86/82 1.0
≥ 0,91 47/40 1.61 
(0.83–3.17)
57/60 1.52 
(0.85–2.75)
91/68 1.68 
(0.95–2.99)
136/106 1.12 
(0.70–1.97)
aAdjusted for age, age at menarche, age at FFTP, number of full term pregnancies, first-degree family history of breast cancer, history of benign 
breast disease, use of oral contraceptives, WHR, alcohol consumption, smoking habits, level of education and postmenopausal use of estrogen.BMC Cancer 2009, 9:115 http://www.biomedcentral.com/1471-2407/9/115
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Table 6: Associations between GSTP1 genotype and breast cancer
Ile/Ile Ile/Val Val/Val Ile/Val and Val/Val
All
Cases, n (%) 315 (57.6) 217 (39.7) 15 (2.7) 232 (42.4)
Controls, n (%) 128 (23.5) 340 (62.5) 76 (14.0) 416 (76.5)
OR (95% CI)a 1.0 0.22 (0.14–0.30) 0.04 (0.01–0.09)b 0.15 (0.07–0.25)
Menopausal status at diagnosis
Premenopausal
Cases, n (%) 101 (54.0) 76 (40.6) 10 (5.4) 86 (46.0)
Controls, n (%) 58 (25.2) 140 (60.9) 32 (13.9) 172 (74.8)
OR (95% CI)a 1.0 0.27 (0.17–0.38) 0.14 (0.06–0.22)b 0.23 (0.16–0.35)
Postmenopausal
Cases, n (%) 214 (59.4) 141 (39.2) 5 (1.4) 146 (40.6)
Controls, n (%) 70 (22.3) 200 (63.7) 44 (14.0) 244 (77.7)
OR (95% CI)a 1.0 0.23 (0.14–0.35) 0.09 (0.02–0.10)b 0.36 (0.24–0.55)
aAdjusted for age, age at menarche, age at FFTP, number of full term pregnancies, first-degree family history of breast cancer, history of benign 
breast disease, use of oral contraceptives, WHR, alcohol consumption, smoking habits, level of education and postmenopausal use of estrogen. bP 
for trend = 0.001.
Table 7: Association of genotypes for the PON1 Q192R and PON1 L55M SNPs and breast cancer
QQ QR RR QR and RR
PON1 Q192R
All
Cases, n (%) 484 (88.5) 50 (9.1) 13 (2.4) 63 (11.5)
Controls, n (%) 340 (62.5) 152 (28.0) 52 (9.5) 204 (37.5)
OR (95% CI)a 1.0 0.58 (0.32–0.99) 0.45 (0.18–0.88)b 0.55 (0.30–0.95)
Menopausal status at diagnosis
Premenopausal
Cases, n (%) 135 (72.2) 41 (21.9) 11 (5.9) 52 (27.8)
Controls, n (%) 144 (62.6) 64 (27.8) 22 (9.6) 86 (37.4)
OR (95% CI) a 1.0 0.73 (0.51–1.43) 0.64 (0.40–1.44)b 0.68 (0.47–1.47)
Postmenopausal
Cases, n (%) 349 (96.9) 9 (2.5) 2 (0.6) 11 (3.1)
Controls, n (%) 196 (62.4) 88 (28.0) 30 (9.6) 118 (37.6)
OR (95% CI) a 1.0 0.12 (0.01–0.33) 0.08 (0.01–0.14)b 0.05 (0.02–0.12)
PON1 L55M LL LM MM LM and MM
All
Cases, n (%) 107 (19.6) 115 (21.0) 325 (59.4) 440 (80.4)
Controls, n (%) 188 (34.6) 125 (23.0) 231 (42.4) 356 (65.4)
OR (95% CI)a 1.0 1.80 (1.36–2.56) 2.81 (1.95–3.64)c 2.42 (1.73–2.99)
Menopausal status at diagnosis
Premenopausal
Cases, n (%) 30 (16.1) 33 (17.6) 124 (66.3) 157 (83.9)
Controls, n (%) 78 (33.9) 70 (30.4) 82 (35.7) 152 (66.1)
OR (95% CI) a 1.0 1.26 (0.66–2.39) 3.83 (2.15–5.87)c 2.67 (1.62–4.15)
Postmenopausal
Cases, n (%) 77 (21.4) 82 (22.8) 201(55.8) 283 (78.6)
Controls, n (%) 110 (35.0) 55 (17.5) 149 (47.5) 204 (65.0)
OR (95% CI) a 1.0 2.23 (1.39–3.40) 2.06 (1.30–2.97)c 2.59 (1.35–3.06)
aAdjusted for age, age at menarche, age at FFTP, number of full term pregnancies, first-degree family history of breast cancer, history of benign 
breast disease, use of oral contraceptives, WHR, alcohol consumption, smoking habits, level of education and postmenopausal use of estrogen. bP 
for trend: all, 0.01; premenopausal, 0.29; postmenopausal, 0.001. cP for trend: all, premenopausal, postmenopausal, 0.001.BMC Cancer 2009, 9:115 http://www.biomedcentral.com/1471-2407/9/115
Page 10 of 14
(page number not for citation purposes)
Table 8: Associations between PON1 Q192R and L55M genotypes and breast cancer
PON1 Q192R QQ QR RR QR and RR
Premenopausal
Controls, n (%) 144 (62.6) 64 (27.8) 22 (9.6) 86 (37.4)
Cases by stage
Local, n (%) 70 (63.6) 30 (27.3) 10 (9.1) 40 (36.4)
OR (95% CI)a 1.0 0.96 (0.55–1.60) 0.94 (0.32–2.17)b 0.95 (0.60–1.62)
Advanced, n (%) 65 (84.4) 11 (14.3) 1 (1.3) 12 (15.6)
OR (95% CI)a 1.0 0.42 (0.23–0.86) 0.23 (0.06–0.85)c 0.33 (0.14–0.60)
Postmenopausal
Controls, n (%) 196 (62.4) 88 (28.0) 30 (9.6) 118 (37.6)
Cases by stage
Local, n (%) 221 (96.9) 6 (2.6) 1 (0.50) 7 (3.1)
OR (95% CI)a 1.0 0.06 (0.01–0.12) 0.04 (0.00–0.23)d 0.05 (0.00–0.10)
Advanced, n (%) 128 (96.9) 3 (2.3) 1 (0.8) 4 (3.1)
OR (95% CI)a 1.0 0.04 (0.01–0.16) 0.02 (0.00–0.25)e 0.05 (0.01–0.11)
PON1 L55M LL LM MM LM and MM
Premenopausal
Controls, n (%) 78 (33.9) 70 (30.4) 82 (35.7) 152 (66.1)
Cases by stage
Local, n (%) 16 (14.6) 25 (22.7) 69 (62.7) 94 (85.4)
OR (95% CI)a 1.0 1.71 (0.78–2.99) 4.12 (2.13–7.98)f 3.05 (1.63–5.78)
Advanced, n (%) 14 (18.2) 8 (10.4) 55 (71.4) 63 (81.8)
OR (95% CI)a 1.0 0.62 (0.22–1.70) 3.71 (1.80–7.53)g 2.28 (1.12–4.49)
Postmenopausal
Controls, n (%) 110 (35.0) 55 (17.5) 149 (47.5) 204 (65.0)
Cases by stage
Local, n (%) 49 (21.5) 52 (22.8) 127 (55.7) 179 (78.5)
OR (95% CI)a 1.0 2.15 (1.28–3.75) 1.94 (1.26–2.98)h 1.88 (1.20–2.59)
Advanced, n (%) 28 (21.2) 30 (22.7) 74 (56.1) 104 (78.8)
OR (95% CI)a 1.0 2.16 (1.15–4.22) 1.98 (1.19–3.36)i 2.00 (1.18–3.29)
aAdjusted for age, age at menarche, age at FFTP, number of full term pregnancies, first-degree family history of breast cancer, history of benign 
breast disease, use of oral contraceptives, WHR, use of non-steroidal anti-inflammatory drugs (NSAID), alcohol consumption, smoking habits, level 
of education and postmenopausal use of estrogen. bP for trend = 0.31; cP for trend = 0.02; d, e , f, g, h, iP for trend = 0.003.
Table 9: Associations between GLO1 genotype and breast cancer
AA AE EE AA and AE
All
Cases, n (%) 119 (21.8) 261 (47.7) 167 (30.5) 428 (78.2)
Controls, n (%) 317 (58.3) 159 (29.2) 68 (12.5) 227 (41.7)
OR (95% CI)a 1.0 4.32 (3.20–5.87) 6.52 (4.51–9.40)b 4.94 (3.75–6.50)
Menopausal status at diagnosis
Premenopausal
Cases, n (%) 39 (20.9) 84 (44.9) 64 (34.2) 148 (79.1)
Controls, n (%) 104 (45.2) 88 (38.3) 38 (16.5) 126 (54.8)
OR (95% CI)a 1.0 2.50 (1.51–4.18) 4.46 (2.50–7.98)b 3.12 (1.96–4.94)
Postmenopausal
Cases, n (%) 80 (22.2) 177 (49.2) 103 (28.6) 280 (77.8)
Controls, n (%) 213 (67.8) 71 (22.6) 30 (9.6) 101 (32.2)
OR (95% CI)a 1.0 6.54 (4.38–9.76) 9.11(5.48–15.05)b 7.35 (5.14–10.53)
aAdjusted for age, age at menarche, age at FFTP, number of full term pregnancies, first-degree family history of breast cancer, history of benign 
breast disease, use of oral contraceptives, WHR, alcohol consumption, smoking habits, level of education and postmenopausal use of estrogen. bP 
for trend: all, 0.01; premenopausal, 0.03; postmenopausal, 0.01.BMC Cancer 2009, 9:115 http://www.biomedcentral.com/1471-2407/9/115
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with a higher PON1 activity had a higher frequency of
genotypes containing the R and L alleles [28,49]. When
the analysis was carried out in subgroups of women
according to their menopausal status at diagnosis, the
PON 192R variant was associated with a decreased risk of
developing BC only among postmenopausal women.
Similarly, the PON 192R variant was associated with a
decreased risk of BC only among premenopausal women
with advanced BC and among postmenopausal patients
with both local and advanced BC when compared to con-
trols. As for CYP17 SNP, our results suggest that also
PON1 Q192R polymorphism may play a different role in
premenopausal and postmenopausal BC etiology. In
addition, exogenous factors, environmental conditions,
dietary habits and life-style other than genetic compo-
nents alone may play a role in determining paraoxonase
enzyme activity. Moreover, findings from the present
study about the association of PON1-192R variant and BC
risk are consistent with those of Gallicchio et al. [33]. On
the contrary, with regard to L55M SNP, our data are in
agreement with those of Stevens et al. [34].
Regarding GLO1 polymorphism, our results indicate that
the presence of the GLO1 E allele significantly increases
BC risk. This might be explained by the fact that the A to
E substitution, due to the SNP, may determine a confor-
mational modification in the enzyme, leading to an
isoenzyme with a lower detoxification capacity [36]. As
well known, glyoxalase 1 is an efficient antiglycation
defence that decreases the concentration of reactive carb-
onyl compounds, such as methylglyoxal (MG), one of the
most potent precursors of carbonyl stress-related
advanced glycation end-products (AGEs). Consequently,
a decrease in the activity of this enzyme may result in an
accumulation of AGEs in human breast tissues. Since
AGEs, resulting from sugar-derived protein modifications,
are known to play a role in BC pathogenesis and progres-
sion [7,8], it would be expected that the presence of a
lower activity form of GLO1 – the GLO1 allele – may be
predictive about severe consequences for an individual's
BC risk. Indeed, accumulations of AGEs in the serum of
BC patients [7,8] has been recently described. In addition,
we found that the risk of BC associated with the GLO1 E
allele significantly tended to increase according to tumour
stage, thus suggesting a possible role of this polymor-
phism, not only in the development of this neoplasia but
also in progression of local to advanced BC. Since this is
the first study to examine the association between GLO1
Table 10: Associations between GLO1 genotype and breast cancer according to menopausal status and tumor stage
AA AE EE AE and EE
Premenopausal
Controls, n (%) 104 (45.2) 88 (38.3) 38 (16.5) 126 (54.8)
Cases by stage
Local, n (%) 26 (23.6) 50 (45.4) 34 (31.0) 84 (76.4)
OR (95% CI)a 1.0 2.17 (1.16–4.0) 3.58 (1.82–7.08)b 2.66 (1.58–4.57)
Advanced, n (%) 13 (16.9) 34 (44.1) 30 (39.0) 64 (83.1)
OR (95% CI)a 1.0 3.05 (1.35–6.65) 6.29 (2.78–14.34)c 4.08 (2.02–4.20)
Postmenopausal
Controls, n (%) 213 (67.8) 71 (22.6) 30 (9.6) 101 (32.2)
Cases by stage
Local, n (%) 55 (24.1) 98 (43.0) 75 (32.9) 173 (75.9)
OR (95% CI)a 1.0 5.31 (3.39–8.25) 9.64 (5.59–16.82)d 6.63 (4.43–9.95)
Advanced, n (%) 25 (19.0) 79 (59.8) 28 (21.2) 107 (81.0)
OR (95% CI)a 1.0 9.44 (5.40–16.55) 7.99 (3.95–16.30)e 8.66 (4.89–15.20)
aAdjusted for age, age at menarche, age at FFTP, number of full term pregnancies, first-degree family history of breast cancer, history of benign 
breast disease, use of oral contraceptives, WHR, alcohol consumption, smoking habits, level of education and postmenopausal use of estrogen. b, c, 
d, eP for trend = 0.001.
Table 11: Risk's level according to genotypes combination
Cases Controls
Genotype n n ORa 95% CI P
Reference genotype 254 633 1.0
Intermediate risk 643 776 2.32 1.79–2.54 < 0.001
High risk 1291 767 4.22 3.55–5.02 < 0.001
aAdjusted for age, age at menarche, age at FFTP, number of full term 
pregnancies, first-degree family history of breast cancer, history of 
benign breast disease, use of oral contraceptives, WHR, alcohol 
consumption, smoking habits, level of education and postmenopausal 
use of estrogen. ORs are calculated relative to subjects with the 
reference genotype.
Reference genotype GSTP1ValVal-PON1/192RR-PON1/55LL-
GLO1AA.
Intermediate risk: GSTP1IleVal-PON1/192QR-PON1/55LM-
GLO1AE.
High risk: GSTP1IleIle-PON1/192QQ-PON1/55MM-GLO1EE.BMC Cancer 2009, 9:115 http://www.biomedcentral.com/1471-2407/9/115
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A111E polymorphism and the risk of BC, additional
research is required to confirm these findings.
The single SNP associations found in this study did not
withstand correction for multiple testing by Bonferroni
method. Additional data are therefore needed to corrobo-
rate our findings. These may be derived by replication in
other genetic-epidemiological studies, preferably in com-
bination with studies on the functional role of gene prod-
ucts that provide biological plausibility.
We also determined the genotypic and allelic frequencies
of CYP17, GSTP1, PON1-192 and-55 as well as GLO1 pol-
ymorphisms for each considered group (control and
patients). When tested for HWE, the genotypic frequen-
cies were in agreement with those predicted under HWE
only for CYP17 polymorphism. Conversely, there were
statistically significant deviations among the controls
between the observed and expected genotypic frequencies
for all the other polymorphisms. Such deviations, in liter-
ature, have been attributed primarily to a possibility of
genotyping error [50]. We have ruled out this possibility
by inclusion of samples of known genotypes, as positive
RFLP controls and three independent operators con-
firmed genotypes. In addition, the frequencies of the
mutant allele among controls for most of the SNPs under
consideration were not significantly different from those
one observed among Caucasian women in other pub-
lished studies [20,33,51]. Other possible reasons for the
observed deviations could be either genetic drift, migra-
tion, inbreeding, cultural parameters based on religion
beliefs and socio-economic requirements, recent origin/
introduction of the polymorphism, absence of random
mating, and/or a stratification bias. The last possibility
can be ruled out since our sample collection included
individuals of known ethnicity. However, the other fac-
tors cannot be ruled out, since our current sample set is
not appropriate to comment on the selection forces oper-
ating on the population.
Conclusion
In conclusion, the results of this report suggest that poly-
morphisms of genes involved in the oxidative stress con-
trol may play a significant role in the development of BC.
In particular, CYP17 polymorphism may modify the risk
of BC only for certain subgroups, while GSTP1, PON1-
192, PON1-55 and GLO1 polymorphisms appear to be
common genetic traits likely associated with the risk of
BC. However, the results of our exploratory analysis, while
nominally significant, did not withstand correction for
multiple testing. Therefore, further studies are needed to
confirm our findings and to explore the exact molecular
basis of our observations.
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